LGALS3 and renal fibrosis: In murine models, Gal3 inhibitors have been shown to significantly decrease kidney injury in a variety of conditions, including sepsis-associated AKI, renal fibrosis in experimental hyperaldosteronism, hypertensive nephropathy, interstitial fibrosis following transplant, and renal fibrosis in IRI AKI.